Route to three-dimensional fragments using diversity-oriented synthesis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits. The increasing number of clinical candidate drugs developed using FBDD approaches is a testament of the efficacy of this approach. The success of fragment-based methods is highly dependent on the identity of the fragment library used for screening. The vast majority of FBDD has centered on the use of sp 2 -rich aromatic compounds. An expanded set of fragments that possess more 3D character would provide access to a larger chemical space of fragments than those currently used. Diversity-oriented synthesis (DOS) aims to efficiently generate a set of molecules diverse in skeletal and stereochemical properties. Molecules derived from DOS have also displayed significant success in the modulation of function of various “difficult” targets. Herein, we describe the application of DOS toward the construction of a unique set of fragments containing highly sp 3 -rich skeletons for fragment-based screening. Using cheminformatic analysis, we quantified the shapes and physical properties of the new 3D fragments and compared them with a database containing known fragment-like molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery
Schreiber, S. L. (2000) · Science · doi:10.1126/science.287.5460.1964 · Cited by 2,568
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“However, much work remains to be done toward the generation of the optimal screening collection (4).”
BackgroundA Planning Strategy for Diversity‐Oriented Synthesis
Burke, M. D., & Schreiber, S. L. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300626 · Cited by 1,493
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Galloway, W. R. J. D., Isidro-Llobet, A., & Spring, D. R. (2010) · Nature Communications · doi:10.1038/ncomms1081 · Cited by 891
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Towards the Optimal Screening Collection: A Synthesis Strategy
Nielsen, T. E., & Schreiber, S. L. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200703073 · Cited by 551
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity
Sauer, W. H. B., & Schwarz, M. K. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci025599w · Cited by 498
Exploring biology with small organic molecules
Stockwell, B. R. (2004) · Nature · doi:10.1038/nature03196 · Cited by 470
Fink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457
Subirós‐Funosas, R., Prohens, R., Barbas, R., El‐Faham, A., & Albericio, F. (2009) · Chemistry – A European Journal · doi:10.1002/chem.200900614 · Cited by 421
Decomposition of a Key Intermediate in Ruthenium-Catalyzed Olefin Metathesis Reactions
Hong, S. H., Day, M. W., & Grubbs, R. H. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0488380 · Cited by 414
Clemons, P. A., Bodycombe, N. E., Carrinski, H. A., Wilson, J. A., Shamji, A. F., Wagner, B. K., Koehler, A. N., & Schreiber, S. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012741107 · Cited by 346
Self-citationFragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Small molecules: the missing link in the central dogma
Schreiber, S. L. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0705-64 · Cited by 306 · cited 1×
“T elucidation of small-molecule probes that shed light on fundamental and disease-associated biological phenomena is a powerful approach in modern chemical biology (1, 2).”
BackgroundA small molecule that binds Hedgehog and blocks its signaling in human cells
Stanton, B. Z., Peng, L. F., Maloof, N., Nakai, K., Wang, X., Duffner, J. L., Taveras, K. M., Hyman, J. M., Lee, S. W., Koehler, A. N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.142 · Cited by 296
Schreiber, S. L. (2009) · Nature · doi:10.1038/457153a · Cited by 292
Marcaurelle, L. A., Comer, E., Dandapani, S., Duvall, J. R., Gerard, B., Kesavan, S., Lee, M. D., Liu, H., Lowe, J. T., Marie, J.-C., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105119r · Cited by 210
Self-citationFrom fragment to clinical candidate—a historical perspective
Chessari, G., & Woodhead, A. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.007 · Cited by 202
Hung, A. W., Silvestre, H. L., Wen, S., Ciulli, A., Blundell, T. L., & Abell, C. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903821 · Cited by 165
Self-citationHung, A. W., Silvestre, H. L., Wen, S., Ciulli, A., Blundell, T. L., & Abell, C. (2009) · Angewandte Chemie · doi:10.1002/ange.200903821 · Cited by 116
Self-citationHajduk, P. J., Galloway, W. R. J. D., & Spring, D. R. (2011) · Nature · doi:10.1038/470042a · Cited by 111
Fragment-based approaches to enzyme inhibition
Ciulli, A., & Abell, C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.003 · Cited by 109
Drugging challenging targets using fragment-based approaches
Coyne, A. G., Scott, D. E., & Abell, C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.010 · Cited by 86
An Oligomer-Based Approach to Skeletal Diversity in Small-Molecule Synthesis
Spiegel, D. A., Schroeder, F. C., Duvall, J. R., & Schreiber, S. L. (2006) · Journal of the American Chemical Society · doi:10.1021/ja065724a · Cited by 79
Cited by
Rings in Drugs: Miniperspective
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017625 · Cited by 2,543
The use of spirocyclic scaffolds in drug discovery
Zheng, Y., Tice, C. M., & Singh, S. B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.081 · Cited by 1,036
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
Macrocycles In New Drug Discovery
Mallinson, J., & Collins, I. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.93 · Cited by 468
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Metadata
- Authors
- Hung, A. W., Ramek, A., Wang, Y., Kaya, T., Wilson, J. A., Clemons, P. A., & Young, D. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-04-11
- Volume
- 108
- Issue
- 17
- Pages
- 6799-6804
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2142595462
- Cited by
- 268
- References
- 31
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.